卵巢癌干细胞标志物：预后和治疗意义。
Ovarian cancer stem cell markers: prognostic and therapeutic implications.
机构信息
University of Michigan, Cell and Molecular Biology Program, United States.
出版信息
Cancer Lett. 2012 Sep 1;322(1):1-7. doi: 10.1016/j.canlet.2012.02.002. Epub 2012 Feb 11.
Abstract
Cancer stem cells are rare chemotherapy resistant cells within a tumor which can serve to populate the bulk of a tumor with more differentiated daughter cells and potentially contribute to recurrent disease. Ovarian cancer is a disease for which at the time of initial treatment we can obtain complete clinical remission in the majority of patients. Unfortunately, most will relapse and succumb to their disease. This clinical course is in line with the cancer stem cell model. In the past 5 years a significant amount of work has been done to identify cells with characteristics of ovarian cancer stem cells. This review will focus specifically on the markers used to define human ovarian cancer stem cells, the prognostic implications of the expression of these cancer stem cell markers in patient's primary tumors, and the potential of these cancer stem cell markers to serve as therapeutic targets.
摘要
癌症干细胞是肿瘤内罕见的化疗耐药细胞，它们可以产生更多分化的子细胞来填充肿瘤，并可能导致疾病复发。卵巢癌是一种在初始治疗时，我们可以使大多数患者获得完全临床缓解的疾病。不幸的是，大多数患者会复发并死于疾病。这种临床病程与癌症干细胞模型一致。在过去的 5 年中，已经做了大量的工作来鉴定具有卵巢癌干细胞特征的细胞。这篇综述将特别关注用于定义人类卵巢癌干细胞的标志物、这些癌症干细胞标志物在患者原发性肿瘤中的表达的预后意义，以及这些癌症干细胞标志物作为治疗靶点的潜力。
相似文献
1
Ovarian cancer stem cell markers: prognostic and therapeutic implications.卵巢癌干细胞标志物：预后和治疗意义。
Cancer Lett. 2012 Sep 1;322(1):1-7. doi: 10.1016/j.canlet.2012.02.002. Epub 2012 Feb 11.
2
CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells.来自具有层级结构的卵巢癌细胞中的 CD24+细胞富含癌症干细胞。
Oncogene. 2010 May 6;29(18):2672-80. doi: 10.1038/onc.2010.35. Epub 2010 Mar 1.
3
Current approach to epithelial ovarian cancer based on the concept of cancer stem cells.基于癌症干细胞概念的上皮性卵巢癌当前治疗方法。
J BUON. 2012 Oct-Dec;17(4):627-36.
4
[Cancer stem cells in colon cancer].[结肠癌中的癌症干细胞]
Bull Cancer. 2017 Dec;104(12):1072-1074. doi: 10.1016/j.bulcan.2017.10.016. Epub 2017 Nov 16.
5
Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer.针对上皮-间质转化和癌干细胞治疗化疗耐药性卵巢癌
Oncotarget. 2016 Aug 23;7(34):55771-55788. doi: 10.18632/oncotarget.9908.
6
Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.干细胞途径导致卵巢癌临床化疗耐药。
Clin Cancer Res. 2012 Feb 1;18(3):869-81. doi: 10.1158/1078-0432.CCR-11-2188. Epub 2011 Dec 5.
7
Detection of cancer stem cell markers in sarcomas.肉瘤中癌症干细胞标志物的检测
Klin Onkol. 2012;25 Suppl 2:2S16-20.
8
Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.醛脱氢酶与 CD133 联合定义了血管生成性卵巢癌干细胞，预示着患者预后不良。
Cancer Res. 2011 Jun 1;71(11):3991-4001. doi: 10.1158/0008-5472.CAN-10-3175. Epub 2011 Apr 15.
9
Progenitor stem cell marker expression by pulmonary carcinomas.肺腺癌中的祖细胞干细胞标志物表达。
Mod Pathol. 2010 Jun;23(6):889-95. doi: 10.1038/modpathol.2010.68. Epub 2010 Mar 19.
10
Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm.上皮性卵巢癌干细胞：简单模式下的潜在复杂性
Reproduction. 2015 Feb;149(2):R59-70. doi: 10.1530/REP-14-0234. Epub 2014 Oct 9.
引用本文的文献
1
Investigating the Effects of ONC206 Alone and in Combination with Cisplatin on Ovarian Cancer Cell Models.研究ONC206单独及与顺铂联合对卵巢癌细胞模型的影响。
Curr Issues Mol Biol. 2025 Jun 12;47(6):451. doi: 10.3390/cimb47060451.
2
The potential of chimeric antigen receptor -T cell therapy for endocrine cancer.嵌合抗原受体T细胞疗法用于内分泌癌的潜力。
World J Surg Oncol. 2025 Apr 22;23(1):153. doi: 10.1186/s12957-025-03745-x.
3
ChemoID-guided therapy improves objective response rate in recurrent platinum-resistant ovarian cancer randomized clinical trial.在复发性铂耐药卵巢癌随机临床试验中，化疗药物识别引导治疗提高客观缓解率。
NPJ Precis Oncol. 2025 Mar 25;9(1):86. doi: 10.1038/s41698-025-00874-0.
4
Knocking down RAD51AP1 enhances chemosensitivity by inhibiting the self-renewal of CD133 positive ovarian cancer stem-like cells.敲低RAD51AP1可通过抑制CD133阳性卵巢癌干细胞样细胞的自我更新来增强化学敏感性。
Discov Oncol. 2024 Sep 5;15(1):410. doi: 10.1007/s12672-024-01258-9.
5
Integrin-linked kinase-frizzled 7 interaction maintains cancer stem cells to drive platinum resistance in ovarian cancer.整合素连接激酶-卷曲蛋白 7 相互作用维持癌症干细胞，从而导致卵巢癌对铂类耐药。
J Exp Clin Cancer Res. 2024 Jun 1;43(1):156. doi: 10.1186/s13046-024-03083-y.
6
Development and clinical validation of a seven-gene signature based on tumor stem cell-related genes to predict ovarian cancer prognosis.基于肿瘤干细胞相关基因的七基因-signature 的开发和临床验证，用于预测卵巢癌预后。
J Ovarian Res. 2024 Mar 13;17(1):58. doi: 10.1186/s13048-023-01326-8.
7
Immunohistochemistry for Cancer Stem Cell Detection: Principles and Methods.免疫组织化学检测癌症干细胞：原理与方法。
Methods Mol Biol. 2024;2777:19-33. doi: 10.1007/978-1-0716-3730-2_2.
8
The Role of Cancer Stem Cell Markers in Ovarian Cancer.癌症干细胞标志物在卵巢癌中的作用
Cancers (Basel). 2023 Dec 20;16(1):40. doi: 10.3390/cancers16010040.
9
Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools.创新技术在个性化癌症医学中的应用：干细胞与基因编辑工具
ACS Pharmacol Transl Sci. 2023 Nov 14;6(12):1758-1779. doi: 10.1021/acsptsci.3c00102. eCollection 2023 Dec 8.
10
Unveiling the novel immune and molecular signatures of ovarian cancer: insights and innovations from single-cell sequencing.揭示卵巢癌的新型免疫和分子特征：单细胞测序的新见解和创新。
Front Immunol. 2023 Nov 1;14:1288027. doi: 10.3389/fimmu.2023.1288027. eCollection 2023.
本文引用的文献
1
Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.干细胞途径导致卵巢癌临床化疗耐药。
Clin Cancer Res. 2012 Feb 1;18(3):869-81. doi: 10.1158/1078-0432.CCR-11-2188. Epub 2011 Dec 5.
2
Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model.抑制 Hedgehog 信号通路拮抗浆液性卵巢癌在原代异种移植模型中的生长。
PLoS One. 2011;6(11):e28077. doi: 10.1371/journal.pone.0028077. Epub 2011 Nov 29.
3
Preclinical evaluation of Mab CC188 for ovarian cancer imaging.Mab CC188 用于卵巢癌成像的临床前评估。
Int J Cancer. 2012 Sep 15;131(6):1351-9. doi: 10.1002/ijc.27380. Epub 2012 Jan 11.
4
CD133 expression associated with poor prognosis in ovarian cancer.CD133 表达与卵巢癌预后不良相关。
Mod Pathol. 2012 Mar;25(3):456-64. doi: 10.1038/modpathol.2011.170. Epub 2011 Nov 11.
5
The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells.干细胞标志物 prominin-1/CD133 在人结肠癌 Caco-2 细胞摄取转铁蛋白和铁代谢中的重要性。
PLoS One. 2011;6(9):e25515. doi: 10.1371/journal.pone.0025515. Epub 2011 Sep 26.
6
Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer.上皮性卵巢癌干细胞的流行率与早期卵巢癌的复发相关。
J Oncol. 2011;2011:620523. doi: 10.1155/2011/620523. Epub 2011 Aug 29.
7
BMP activity controlled by BMPER regulates the proinflammatory phenotype of endothelium.骨形态发生蛋白活性受骨形态发生蛋白受体（BMPER）调控，调节内皮细胞的促炎表型。
Blood. 2011 Nov 3;118(18):5040-9. doi: 10.1182/blood-2011-03-339762. Epub 2011 Sep 7.
8
A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.A6 肽激活 CD44 黏附活性，诱导 FAK 和 MEK 磷酸化，并抑制 CD44 表达细胞的迁移和转移。
Mol Cancer Ther. 2011 Nov;10(11):2072-82. doi: 10.1158/1535-7163.MCT-11-0351. Epub 2011 Sep 1.
9
Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome.具有 CD117 表型的卵巢癌细胞具有高度致瘤性，并与化疗结果相关。
Exp Mol Pathol. 2011 Oct;91(2):596-602. doi: 10.1016/j.yexmp.2011.06.005. Epub 2011 Jul 20.
10
Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response.透明质酸包覆的纳米颗粒：分子量对 CD44-透明质酸相互作用和免疫反应的影响。
J Control Release. 2011 Dec 10;156(2):231-8. doi: 10.1016/j.jconrel.2011.06.031. Epub 2011 Jul 2.
Zotero 插件